Disruption of the PHRF1 Tumor Suppressor Network by PML-RARα Drives Acute Promyelocytic Leukemia Pathogenesis  by Prunier, Céline et al.
ReportDisruption of the PHRF1 Tumor Suppressor Network
by PML-RARa Drives Acute Promyelocytic Leukemia
PathogenesisGraphical AbstractHighlightsd PML-RARa stabilizes TGIF by antagonizing PHRF1 activity
d PML-RARa and PHRF1 form mutually exclusive complexes
with TGIF
d Enforced expression of PHRF1 restores TGF-b signaling in
APL blasts
d Suppression of PHRF1 activity contributes to the
pathogenesis of APLPrunier et al., 2015, Cell Reports 10, 883–890
February 17, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.01.024Authors
Ce´line Prunier, Ming-Zhu Zhang, ...,
Guri Tzivion, Azeddine Atfi
Correspondence
azeddine.atfi@inserm.fr
In Brief
Disruption of the TGF-b tumor
suppressor network by PML-RARa
contributes to acute promyelocytic
leukemia pathogenesis, but the
underlying mechanisms remain unclear.
Prunier et al. show that PML-RARa
associates with and engages TGIF in a
complex that compromises its interaction
with PHRF1, culminating in TGIF accrual
and attenuated TGF-b signaling.
Cell Reports
ReportDisruption of the PHRF1 Tumor Suppressor Network
by PML-RARa Drives Acute Promyelocytic
Leukemia Pathogenesis
Ce´line Prunier,1,4 Ming-Zhu Zhang,2,4 Santosh Kumar,3 Laurence Levy,1 Olivier Ferrigno,1 Guri Tzivion,3
and Azeddine Atfi1,3,*
1Laboratory of Cell Signaling and Carcinogenesis, INSERM UMRS938, 184 Rue du Faubourg St-Antoine, 75571 Paris, France
2Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA 02115, USA
3Department of Biochemistry, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS 39216, USA
4Co-first author
*Correspondence: azeddine.atfi@inserm.fr
http://dx.doi.org/10.1016/j.celrep.2015.01.024
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).SUMMARY
PHRF1 functions as an essential component of the
TGF-b tumor suppressor pathway by triggering
degradation of the homeodomain repressor factor
TGIF. This leads to redistribution of cPML into the
cytoplasm, where it coordinates phosphorylation
and activation of Smad2 by the TGF-b receptor. In
acute promyelocytic leukemia (APL), acquisition of
PML-RARa is known to impede critical aspects of
TGF-b signaling, including myeloid differentiation.
Although these defects are thought to rely on sup-
pression of cPML activity, the mechanisms underly-
ing this phenomenon remain enigmatic. Here, we
find that an abnormal function of PML-RARa is to
interfere with TGIF breakdown, presumably by
competing with PHRF1 for binding to TGIF, culmi-
nating in cPML sequestration and inactivation. En-
forcing PHRF1 activity is sufficient to restore TGF-b
cytostatic signaling in human blasts and suppress
APL formation in a mouse model of APL, providing
proof-of-concept data that suppression of PHRF1
activity by PML-RARa represents a critical determi-
nant in APL pathogenesis.
INTRODUCTION
The PML tumor suppressor plays an important role in constrain-
ing both hematological and non-hematological malignancies, yet
much remains to be learned about how it is regulated or how it
might be inactivated during tumor progression (de The´ et al.,
2012; Dos Santos et al., 2013). In the vast majority of acute pro-
myelocytic leukemia (APL) patients, PML is fused to RARa,
engendering an oncogenic fusion protein PML-RARa capable
of initiating acute leukemia by suppressing differentiation along
themyeloid lineage (Grignani et al., 1993; Scaglioni and Pandolfi,
2007). In transgenic mice, ectopic expression of PML-RARa in
themyeloid lineage causes leukemiawith features of APL, under-Cescoring unequivocally the causal role for PML-RARa acquisition
in APL development (Brown et al., 1997). Functionally, PML-
RARa was initially thought to act as a transcriptional repressor
to antagonize myeloid differentiation and promote APL-initiating
cell self-renewal. However, there is accumulating evidence that
PML-RARa can also interfere with the ability of the PML isoforms
encoded by the intact remaining allele to elicit a variety of tumor-
suppressive functions, such as growth arrest and terminal differ-
entiation (de The´ and Chen, 2010; Licht, 2006; Salomoni and
Pandolfi, 2002; Scaglioni and Pandolfi, 2007). For instance,
PML-RARa has been shown to antagonize cPML activity that is
instrumental to integration of the transforming growth factor
beta (TGF-b) tumor suppressor program (Lin et al., 2004). Yet,
the molecular mechanisms by which PML-RARa disables
cPML function in TGF-b signaling remain to be elucidated.
TGF-b signaling is initiated by the formation of a complex con-
sisting of two types of transmembrane Ser/Thr kinase receptor,
TbRI and TbRII (Massague´, 2008). TGF-b binding to TbRII in-
duces recruitment and phosphorylation of TbRI, which in turn
phosphorylates Smad2 and Smad3 (Smad2/3), a process facili-
tated by the adaptor protein SARA (Massague´, 2008). The role
of cPML in TGF-b signaling is to bridge together Smad2/3 and
SARA and bring that complex within the proximity of TbRI (Lin
et al., 2004; Seo et al., 2006). Phosphorylation of Smad2/3 in-
duces association with Smad4 and translocation of the com-
plexes to the nucleus, where they regulate expression of TGF-b
target genes (Massague´, 2008).
The phosphorylation of Smad2/3 can be limited from the
nucleus by TGIF (TG-interacting factor), which belongs to the
TALE family of homeodomain proteins. Mechanistically, TGIF in-
teracts with and interferes with the nucleocytoplasmic transit of
cPML, thereby precluding assembly of the cPML/SARA complex
and concomitant phosphorylation of Smad2/3 (Ettahar et al.,
2013; Faresse et al., 2008; Lin et al., 2004; Seo et al., 2006). Be-
sides cPML, TGIF has also been shown to interact with retinoic
acid receptor alpha (RARa) and repress its transcriptional activity
(Bartholin et al., 2006).
Collectively, these observations underscored an ability of TGIF
to associate with both cPML and RARa, raising the question of
whether there is any functional interplay between TGIF andll Reports 10, 883–890, February 17, 2015 ª2015 The Authors 883
PML-RARa. In our efforts to probe this possibility, we found that
acquisition of PML-RARa in human APL blasts caused abnormal
TGIF accrual, ultimately culminating in cPML inactivation and
suppression of TGF-b signaling. We went on to investigate the
underlying mechanisms, focusing our attention on PHRF1, a
TGIF ubiquitin ligase recently identified in our laboratory as an
essential component of the TGF-b-signaling pathway (Ettahar
et al., 2013). Remarkably, we found that PML-RARa associated
with and engaged TGIF in a physical complex that compromises
its interaction with PHRF1, leading to excessive TGIF accumula-
tion. Such a mechanism seems to play an important role in APL
progression, because restoration of PHRF1 activity was suffi-
cient to trigger myeloid differentiation in human blasts and
restrain APL progression in a mouse model of APL. Therefore,
our findings that expression of PML-RARa impinges on PHRF1
function shed new mechanistic insights into the etiology of
APL, likely paving the way for therapeutic breakthroughs to
curb this life-threatening disease.
RESULTS AND DISCUSSION
PML-RARa Blocks PHRF1-Induced TGIF Degradation
PML-RARa has been shown to hamper TGF-b-induced growth
arrest and myeloid cell differentiation (Grignani et al., 1993; Lin
et al., 2004), but the molecular mechanisms underlying this phe-
nomenon remain elusive. Our published data that TGIF restricts
TGF-b signaling by antagonizing cPML prompted us to explore
whether PML-RARa could disrupt the interplay between TGIF
and cPML, in turn endowing leukemia cells with the capability
to evade TGF-b cytostatic signaling (Ettahar et al., 2013; Fare-
sse et al., 2008; Seo et al., 2006). We initially tested this possi-
bility by employing NB4 blasts, which derive from an APL patient
and exhibit the particularity to undergo proteasomal degrada-
tion in response to retinoic acid (RA) (Lanotte et al., 1991; Lin
et al., 2004). Quite surprisingly, RA stimulation caused a marked
decrease in the expression levels of the TGIF protein (Figure 1A).
Under these experimental conditions, RA stimulation did not
cause any significant change in the expression of PHRF1 (Fig-
ure 1A), an E3 ubiquitin ligase that governs TGIF degradation
(Ettahar et al., 2013). Likewise, there were no significant
changes in the expression of other major components of the
TGF-b-signaling pathway, including TbRI, TbRII, SARA, cPML,
Smad2, Smad3, and Smad4 (Figures 1G, 3A–3C, and S3A;
data not shown). As another specificity control, RA stimulation
was void of any effect on the abundance of the TGIF protein in
the human Burkitt’s lymphoma cell line BL41 bearing constitu-
tively active c-Myc, the human leukemia cell line K562 harboring
the oncogenic fusion protein Bcr-Abl, or mouse embryonic fi-
broblasts (MEFs) (Figure S1A), indicating that RA induced
decreased TGIF expression by triggering PML-RARa degrada-
tion. In further support to the notion that PML-RARa stabilizes
TGIF, NB4 cells display higher TGIF expression compared to
K562 or BL41 cells (Figure S1A). It is also noteworthy that deple-
tion of RARa or depletion/deletion of PML failed to decrease
TGIF expression (Figures S1A–S1C), highlighting an acquired
ability of PML-RARa to engender a gain of function that can-
not be fulfilled by either protein alone. We independently vali-
dated this finding by demonstrating increased TGIF abundance884 Cell Reports 10, 883–890, February 17, 2015 ª2015 The Authorsfollowing induction of PML-RARa expression in the human he-
matopoietic precursor cells, U937-MTPR9 (Figure 1B), which
carry PML-RARa under the control of a zinc-inducible promoter
(Grignani et al., 1993). Here again, expression of PML-RARa had
no effect on the expression of PHRF1 or any other components
of TGF-b signaling described earlier (Figures 1B, S1E, and S4B;
data not shown). Collectively, these findings revealed an ability
of PML-RARa to trigger aberrant TGIF accrual, providing an
initial hint for how PML-RARa disrupts TGF-b signaling in APL
blasts.
To investigate whether PML-RARa increases expression of
the TGIF protein by preventing its degradation and, if so,
whether this process occurs via PHRF1, we undertook the
following approaches. First, we challenged NB4 blasts with RA
in the presence or absence of MG132 and found that blocking
the proteasome machinery was effective in preventing PML-
RARa degradation and the associated decline in TGIF abun-
dance (Figure 1C). Second, decreasing expression of PML-
RARa in NB4 blasts by RA treatment or, conversely, inducing
expression of PML-RARa in U937-MTPR9 cells by Zn treatment
had little or no effect on TGIF mRNA expression (Figure S1D).
Third, expression of PML-RARa increased expression of the
TGIF protein from a TGIF transgene driven by a constitutive
CMV promoter (Figure S1E), further suggesting that PML-
RARa fosters TGIF abundance by a transcriptional-independent
mechanism. Fourth, we analyzed the half-life of the TGIF protein
in cycloheximide (CHX)-chase experiments and found that RA
stimulation accelerated the turnover of the TGIF protein (Fig-
ure 1D). Fifth, we conducted comparative analyses using wild-
type TGIF and a PHRF1-resistant mutant, TGIF.K130R, and
the result underscored an inability of PML-RARa to further sus-
tain expression of TGIF.K130R, as compared to the wild-type
counterpart (Figure S1E). Sixth, stimulation of NB4 blasts with
RA resulted in increased polyubiquitination of endogenous
TGIF (Figure 1E). Seventh, exposure of U937-MTPR9 cells to
Zn decreased TGIF polyubiquitination to an extent similar to
that observed for the PHRF1-resistant mutant, TGIF.K130R
(Figure 1F). Finally, depleting PHRF1 in NB4 blasts prevented
RA-induced TGIF decay, despite the strong decrease in the
expression level of PML-RARa (Figure 1G). Taken together,
these data strongly suggest that expression of PML-RARa inter-
feres with PHRF1-induced TGIF polyubiquitination and degra-
dation by the proteasome.
PML-RARa Competes with PHRF1 for Binding to TGIF
Previous studies fromour and other laboratories have shown that
TGIF can interact with both cPML and RARa in many cell sys-
tems (Bartholin et al., 2006; Faresse et al., 2008; Seo et al.,
2006). Coimmunoprecipitation experiments confirmed the inter-
action of TGIF with cPML or RARa as well as the disruption of the
TGIF/RARa complex by RA (Figures 2B, S2B, S2C, and S2E–
S2H). As PML-RARa retains large segments of both proteins
(de The´ et al., 1991), we considered the possibility that PML-
RARa may associate with and divert TGIF from PHRF1, thereby
causing increased TGIF abundance. In fact, we found that
expression of PML-RARa caused redistribution of TGIF into
nuclear microspeckles, providing an initial indication that
TGIF interacts with PML-RARa (Figure 2A). Subsequent
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Figure 1. PML-RARa Expression Stabilizes TGIF
(A and B) Expression of TGIF, PML-RARa, or PHRF1 in NB4 blasts exposed to RA for various times (A) or U937-MTPR9 cells treated with Zn for 24 hr (B) was
analyzed by immunoblotting.
(C) NB4 cells were incubated with RA and/or MG132 for the indicated times and analyzed by immunoblotting.
(D) NB4 blasts were incubated with cycloheximide (CHX) alone or together with RA for various times before being analyzed by immunoblotting. The half-life of
TGIF is indicated.
(E) NB4 blasts were treated with RA for 24 hr before being incubated with MG132 for the last 6 hr. Endogenous TGIF polyubiquitination was analyzed by
coimmunoprecipitation.
(F) Transfected U937-MTPR9 cells were treated with Zn for 24 hr before being incubated with MG132 for the last 6 hr. Lysates were pulled down (PD) with nickel-
Sepharose and immunoblotted with anti-HA.
(G) NB4 blasts expressing sh-Scram or sh-PHRF1 were treated with RA for 24 hr and analyzed by immunoblotting.
See also Figure S1.coimmunoprecipitation studies revealed a robust interaction be-
tween endogenous PML-RARa and TGIF in NB4 blasts, and this
decreased upon RA stimulation (Figure 2B). Strikingly, concom-
itant with the decrease in the PML-RARa/TGIF interaction, the
PHRF1/TGIF interaction was increased, despite the strong
decrease in the total pool of TGIF (Figure 2B), suggesting that
PML-RARa and PHRF1 might compete for binding to TGIF. We
also performed coimmunoprecipitation experiments using
U937-MTPR9 cells and found that inducing PML-RARa expres-
sion by Zn stimulation was effective in promoting assembly ofCethe PML-RARa/TGIF complex, likely occurring at the expense
of the PHRF1/TGIF complex (Figure S2A). Further evidence
that PML-RARa and PHRF1 competitively share TGIF was ob-
tained by showing that PML-RARa was able to displace the
PHRF1/TGIF interaction in a dose-response manner and vice
versa (Figures 2C and 2D). This effect is specific to PML-RARa,
as overexpression of PML or RARa separately did not affect
the expression levels of TGIF or its association with PHRF1 (Fig-
ures S2B and S2C). In our attempt to unravel the basis of these
competitive interactions, we conduced an in depth analysis ofll Reports 10, 883–890, February 17, 2015 ª2015 The Authors 885
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Figure 2. PML-RARa Competes with PHRF1 for Binding to TGIF
(A) PML/ MEFs were transfected with pEGFP-TGIF in the absence or presence of PML-RARa and immunostained with anti-PML and DAPI.
(B) NB4 blasts were treated with RA for 24 hr, and the association of TGIF with PML-RARa, RARa, or PHRF1 was analyzed by coimmunoprecipitation.
(C and D) U937 cells were transfected with the indicated combination of PML-RARa, HA-TGIF, and Flag-PHRF1, and the association of HA-TGIF with PML-RARa
or Flag-PHRF1 was analyzed by coimmunoprecipitation.
(E) U937 cells were transfected with pG5E1b-Luc together with Gal4-PML-RARa and VP16-TGIF deletion mutants. Luciferase activity was measured, and data
are expressed as mean ± SD of triplicates.
(F) The interaction of PML-RARa with TGIF deletion mutants in transfected U937 cells was analyzed by coimmunoprecipitation.
See also Figure S2.the TGIF/PML-RARa interaction by means of coimmunoprecipi-
tation and mammalian two-hybrid assays. We found that PML-
RARa displayed affinity for two distinct regions in TGIF (Figures
2E, 2F, and S2D), suggesting that association of PML-RARa
with TGIF might mask the PHRF1-binding site in TGIF. In further
support to this notion, PML interacted with the N terminus of
TGIF, whereas RARa interacted with the C terminus of TGIF (Fig-
ures S2E–S2H). Interestingly, disrupting the PHRF1-binding
domain (TGIFD148-177) in TGIF (Ettahar et al., 2013) caused a
significant decrease in the TGIF/PML-RARa interaction (Figures
2E and 2F), supporting the hypothesis that PML-RARa and
PHRF1 compete for the same domain in TGIF. Together, these
results provide strong evidence that PML-RARa and PHRF1
form mutually exclusive complexes with TGIF.
Restoration of PHRF1 Activity in APL Blasts Rescues
TGF-b Signaling
The results outlined so far revealed an acquired ability of PML-
RARa to implement excessive TGIF accumulation, presumably
by disrupting its interaction with PHRF1. In so doing, PML-
RARa could conceivably antagonize cPML function in TGF-b886 Cell Reports 10, 883–890, February 17, 2015 ª2015 The Authorssignaling. Several lines of evidence support this theory. First,
treatment of NB4 cells with RA increased the interaction between
endogenous cPML and SARA (Figure 3A), which is known to take
place in the cytoplasm (Lin et al., 2004; Seo et al., 2006). A similar
effect was observed when the interaction of cPML with TbRI was
examined (Figure S3A). Second, exposure of NB4 blasts to RA
elicited a marked increase in TGF-b-induced Smad2 phosphor-
ylation but failed to elicit any response in NB4 cells depleted
for cPML (Figure 3B), which is in consonance with previous ob-
servations that PML-RARa blocks TGF-b signaling by antago-
nizing cPML (Lin et al., 2004). Third, depleting PHRF1 in NB4
blasts blunted RA-induced Smad2 phosphorylation (Figure 3C),
directly linking PHRF1 to the PML-RARa/cPML/Smad2 axis.
Finally, depleting TGIF restored RA-induced Smad2 phosphory-
lation in cells depleted for PHRF1 (Figure 3C), reinforcing the hy-
pothesis that PHRF1 influences the PML-RARa/cPML/Smad2
axis by enforcing TGIF degradation. Taken together with our
earlier protein-protein interaction analyses, these findings
strongly suggest that PML-RARa engages TGIF in a complex
that compromises its association with PHRF1, a mechanistic
model that likely explains why expression of PML-RARa triggers
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Figure 3. PML-RARa Suppresses TGF-b Signaling by Disrupting PHRF1-Driven TGIF Degradation
(A) NB4 blasts were treated with RA for 24 hr, and the association of endogenous cPML and SARA was analyzed by coimmunoprecipitation.
(B and C) NB4 blasts expressing the indicated combinations of shRNAs were cultured with RA for 24 hr. Then, cells were treated with TGF-b for 30 min and
phosphorylation of Smad2 was analyzed by immunoblotting using anti-phospho-Smad2 (pSmad2) antibody.
(D and E) NB4 blasts were transfected with ARE3-Lux together with FAST1 and the indicated combination of expression vectors and treated with RA for 24 hr
before being treated with TGF-b for the last 16 hr. Luciferase activity was measured, and data are expressed as mean ± SD (n = 3).
See also Figure S3.excessive TGIF accumulation in blasts, in turn setting an attenu-
ated TGF-b/Smad signaling.
To validate this scenario, we extended our analysis to the
TGF-b transcriptional program, using the ARE3-Lux reporter, a
surrogate readout of Smad2 transcriptional activity. As shown
in Figure 3D, enforced expression of PHRF1 increased the sensi-
tivity of NB4 blasts to TGF-b-induced transcription even in the
absence of RA stimulation. This increase likely depends on
TGIF degradation, as enforced expression of a catalytic inactive
mutant of PHRF1, PHRF1.CA, exerted a dominant-negative ef-
fect that was completely reversed in cells depleted for TGIF (Fig-
ure 3D). Likewise, the PHRF1 rescue effect was also dependent
on cPML, because its depletion was sufficient to render again
NB4 blasts overexpressing PHRF1 unresponsive to TGF-b (Fig-
ure 3E). These observations were independently validated using
a Smad3-specific reporter (Figures S3B and S3C). Based on
these findings, it is tempting to suggest that the blockade of
TGF-b signaling in APL blasts harboring PML-RARa might
stem from abnormal TGIF accrual and the resulting cPML inacti-
vation rather than other mechanisms.
To further challenge this scenario, we interrogated the ability
of PML-RARa to confer resistance to TGF-b-induced myeloidCedifferentiation, a prominent hallmark of APL development
(Grignani et al., 1993). To this end, we used U937-MTPR9
cells, which undergo massive monocytic differentiation in res-
ponse to TGF-b signaling in the absence of PML-RARa ex-
pression (Grignani et al., 1993). Congruent with the literature,
inducing PML-RARa in U937-MTPR9 cells resulted in a potent
decrease in TGF-b-induced myeloid differentiation (Figures
4A and S4A). Strikingly, overexpression of PHRF1 blunted
this PML-RARa inhibitory effect, whereas overexpression of
PHRF1.CA elicited the opposite response (Figures 4A and
S4A). Of note, simultaneous TGIF depletion was sufficient to
restore TGF-b responsiveness in PHRF1.CA-expressing cells
(Figures 4A and S4A), demonstrating that PHRF1.CA exerts
its dominant inhibitory effect via stabilization of endogenous
TGIF. Finally, depleting cPML disrupted the ability of PHRF1
to restore TGF-b-induced myeloid differentiation (Figures
S4B and S4C). Similar results were obtained in experiments
investigating the granulocytic differentiation of NB4 cells in
response to RA and TGF-b stimulation (Figure 4B). Taken
together, these results provide strong evidence that disruption
of PHRF1 function contributes to resistance of APL blasts to
TGF-b signaling.ll Reports 10, 883–890, February 17, 2015 ª2015 The Authors 887
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Figure 4. PML-RARa Drives APL by Impeding PHRF1-Driven TGIF Degradation
(A) U937-MTPR9 cells stably expressing the indicated expression vectors were cultured with Zn for 16 hr before being treated with TGF-b plus vitamin D3 (TGF-b/
D3) for 5 days. Cell differentiation was evaluated by determining the number of positive CD14 cells. Data are expressed as mean ± SD (n = 3).
(B) NB4 cells were transiently transduced with the indicated combinations of lentiviruses and cultured with or without RA and TGF-b for 5 days. Cell differentiation
was evaluated by determining the number of positive CD11b cells. Data are expressed as mean ± SD (n = 3).
(C and D) MRP8 blasts were stably transfected with Dox-repressible Flag-PHRF1 or Flag-PHRF1.CA alone or together with HA-TGIF.K130R. Expression of
PHRF1 or TGIF was determined by direct immunoblotting (C). MRP8 stable cell lines were transplanted to FVBmice, and survival was recorded in a Kaplan-Meier
graph (D).
(E and F) Representative H&E staining pictures of liver and spleen (E) or weights of spleen (F) of mice scarified in (D).
See also Figure S4.Restoration of PHRF1 Activity Suppresses APL
Formation In Vivo
Besides APL, TGF-b cytostatic signaling is disrupted in many
types of human leukemia, suggesting the existence of diverse
mechanisms that disable the TGF-b tumor-suppressive function
in human hematological malignancies (Blank and Karlsson,
2011; Dong and Blobe, 2006; Lin et al., 2004). To investigate888 Cell Reports 10, 883–890, February 17, 2015 ª2015 The Authorswhether restoration of TGF-b signaling in APL blasts could influ-
ence APL progression in vivo, we conducted transplantation
experiments using APL blasts from hMRP8-PML/RARa mice,
which harbor constitutive expression of PML-RARa in the he-
matopoietic lineage (Brown et al., 1997). In comparison to the
native MRP8-PML/RARa transgenic mice, MRP8-transplanted
mice develop APL with similar features but with very short
latency, thus enabling rapid generation of APL-bearing mice.
Initial biochemical experiments showed that exposure of MRP8
cells to RA induced TGIF degradation, and this was accompa-
nied with increased association of TGIF with PHRF1 and
concomitant disassembly of the TGIF/PML-RARa complex (Fig-
ures S4D and S4E). Next, we generated MRP8 blasts stably ex-
pressing wild-type PHRF1 or PHRF1.CA under the control of a
doxycycline (Dox)-repressible promoter (Figure 4C), with the
aim to circumvent the PHRF1-dependent myeloid differentiation
until transplantation into recipient mice that were maintained un-
der Dox-free conditions, thus enabling expression of PHRF1 or
PHRF1.CA. During the 90 days observation period, all 15 mice
transplanted with control or MRP8-PHRF1.CA blasts developed
fatal APL, whereas 14 out of 15 mice transplanted with MRP8-
PHRF1 remained healthy and free of tumors (Figure 4D). Of
note, the body of the mouse that died unexpectedly (without
any apparent complication) was severely decomposed, preclud-
ing any analysis to assess for the presence of MRP8-PHRF1
blasts. Interestingly, we noticed that expression of PHRF1.CA
resulted in a slight but significant decrease in mice survival
when compared to mice receiving MRP8-vector blasts (Fig-
ure 4D), which is in good agreement with our earlier observations
that PHRF1.CA functions as a dominant-negative mutant. To
substantiate these observations, we carried histopathological
experiments to assess infiltration of immature myeloid cells
into the liver or spleen, a process known to impinge on their
integrity (Omidvar et al., 2013). In contrast to mice transplanted
with MRP8-vector or MRP8-PHRF1.CA cells, we were unable
to see any alterations in the liver or spleen of mice transplanted
with MRP8-PHRF1 cells (Figure 4E). These findings were inde-
pendently validated by demonstrating the absence of exoge-
nous PHRF1 expression in the spleen of MRP8-PHRF1 mice
as well as increased weight of the spleen of MRP8-vector or
MRP8-PHRF1.CA mice compared to MRP8-PHRF1 mice (Fig-
ures 4F and S4F). To directly demonstrate that this PHRF1 tu-
mor-suppressive function is mediated via TGIF degradation,
we performed similar in vivo transplantation experiments using
MRP8-PHRF1 cells expressing the PHRF1-resistant mutant,
TGIF.K130R, surmising that preventing TGIF degradation would
be sufficient to oppose PHRF1-driven APL suppression. In fact,
expression of TGIF.K130R in MRP8-PHRF1 blasts restored APL
formation in mice (Figures 4C–4F and S4H). In an alternative
complementary approach, depleting TGIF blocked both RA-
induced granulocytic differentiation of MRP8 cells in vitro and
APL formation by these cells in vivo (Figures S4G and S4H).
Together, these findings suggest that disruption of PHRF1-
driven TGIF degradation by PML-RARa is instrumental in the
pathogenesis of APL.
Concluding Remarks
Acquisition of the PML-RARa oncogene represents by far the
most common basis of inactivation of the PML tumor suppressor
in APL. Despite the tremendous progressmade in understanding
the etiology of APL, the molecular mechanisms by which PML-
RARa drives leukemogenesis remain unclear. Therefore, our
findings that acquisition of PML-RARa impinges on the PHRF1
tumor suppressor network not only hold tantalizing promises
for unraveling mechanistic paradigms of APL pathogenesis butCealso raise the provocative concept that the PML-RARa/TGIF/
PHRF1 module could be an important target for elaborating in-
novative therapeutic strategies to combat APL malignancies
that develop resistant to conventional drugs, such as RA. For
instance, identifying drugs that impede the interaction between
PML-RARa and TGIF could restore the ability of PHRF1 to trigger
TGIF degradation, ultimately leading to APL blast differentiation
and attendant leukemia regression despite the resistance of
PML-RARa to RA.
EXPERIMENTAL PROCEDURES
Cell Culture
HEK293T, K562, MEFs, and NB4 cells were cultured in DMEM supplemented
with 10% fetal calf serum (FCS). U937-MTPR9 and MRP8 cells were main-
tained in RPMI supplemented with 10% FCS. Stable cell lines were maintained
in media containing G418 (500 mg/ml), puromycin (10 mg/ml), and/or Zeocin
(500 mg/ml).
Immunoprecipitation and Immunoblotting
Cell lysates were prepared using TNMG buffer as previously described (De-
mange et al., 2009). They were then incubated with antibody for 2 hr, followed
by adsorption to Sepharose-coupled protein G for 1 hr. Immune complexes
were separated by SDS-PAGE and analyzed by immunoblotting. In CHX-
chase experiments, the expression level of TGIF was determined by scanning
laser densitometry.
Myeloid Differentiation Assay
Myeloid differentiation was examined as previously described (Grignani et al.,
1993). Briefly, cells were incubated with anti-CD14 or anti-CD11b antibody for
60 min at 4C. Then, cells were incubated for 60 min at 4C with fluorescein-
labeled secondary antibody and analyzed by FACS using a FACSCaliber (Bec-
ton Dickinson).
Transplantation Experiments
MRP8 cells from hMRP8-PML/RARa mice were described previously (Omid-
var et al., 2013). Leukemia was propagated by intravenous injection of blasts
(106 viable MRP8 cells) into 6-week-old syngeneic FVB mice. Animal handling
was done according to the guidelines of Institutional Animal Care and Use
Committee (IACUC) of UMMC.
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